ATM and neoplasm: In addition, a preclinical study confirmed the therapeutic efficacy of DNA-PK inhibitors in ATM-deficient tumors, probably because ATM and DNA-PK are jointly involved in the NHEJ process and the survival of ATM-deficient tumor cells is highly dependent on DNA-PK signaling, which activates the DNA damage repair process (Xue et al., 2022).